ஜர்னல் ஆஃப் பார்மகோகினெடிக்ஸ் & எக்ஸ்பெரிமென்டல் தெரபியூட்டிக்ஸ்

சுருக்கம்

Oral Bioavailability enhancement of Ganciclovir by Chitosan Nanoparticles: Pharmacokinetics Studies

Rajendra Kotadiya

Ganciclovir (GCV), an acyclovir analogue, proved to have excellent antiviral activity against human Cytomegalovirus (CMV), a leading cause of congenital infections worldwide. Ganciclovir (GCV), given intravenously (i.v.) at 5 mg/kg of body weight once daily, or orally as capsules at 1,000 mg three times a day (TID), is the standard drug regimen for both the treatment and prevention of CMV disease. However, i.v. GCV is an inconvenient drug regimen for long-term use, requiring i.v. catheters and might leads to sepsis. Although GCV capsules are more convenient, the low relative bioavailability (6%) limits the concentrations in serum.  In recent years, one promising delivery system with improved oral bioavailability, chitosan nanoparticles (CNs) have attracted considerable attention^1,2. Hence, in present investigation various oral formulation containing GCV along with chitosan nanoparticles containing GCV have been developed and their in vivo studies using Wistar rats have been performed.